Acorda Therapeutics upgraded to "outperform"
09/07/10 - Robert W. Baird
NEW YORK, September 7 (newratings.com) - Analysts at Robert W Baird upgrade Acorda Therapeutics Inc (ACOR) from "neutral" to "outperform." The target price is set to $40.
Share Recommend this article to a friend add ACOR to my stocks and get e-mail alerts on Acorda Therapeutics Inc.
|03/29/10||Acorda Therapeutics initiated with "hold"||Citigroup|
|02/04/10||Acorda Therapeutics downgraded to "neutral"||Robert W. Baird|
|10/15/09||Acorda Therapeutics upgraded to "buy"||Merriman Curhan Ford & Co|